tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Kiniksa provides corporate update
PremiumThe FlyKiniksa provides corporate update
1M ago
Kiniksa Advances KPL-387 Study for Recurrent Pericarditis: What Investors Should Know
Premium
Company Announcements
Kiniksa Advances KPL-387 Study for Recurrent Pericarditis: What Investors Should Know
2M ago
Kiniksa price target raised to $55 from $45 at Goldman Sachs
Premium
The Fly
Kiniksa price target raised to $55 from $45 at Goldman Sachs
4M ago
Kiniksa expects current operating plan to remain cash flow positive
PremiumThe FlyKiniksa expects current operating plan to remain cash flow positive
4M ago
Kiniksa reports Q3 EPS 23c, consensus 37c
Premium
The Fly
Kiniksa reports Q3 EPS 23c, consensus 37c
4M ago
Kiniksa Pharmaceuticals’ Promising Study on KPL-387 for Recurrent Pericarditis
Premium
Company Announcements
Kiniksa Pharmaceuticals’ Promising Study on KPL-387 for Recurrent Pericarditis
4M ago
Kiniksa  granted orphan designation for treatment of pericarditis
PremiumThe FlyKiniksa granted orphan designation for treatment of pericarditis
4M ago
Kiniksa price target raised to $44 from $38 at Wedbush
Premium
The Fly
Kiniksa price target raised to $44 from $38 at Wedbush
4M ago
Kiniksa Pharmaceuticals: Strong Buy Rating Driven by Arcalyst’s Market Success and Promising Pipeline
Premium
Ratings
Kiniksa Pharmaceuticals: Strong Buy Rating Driven by Arcalyst’s Market Success and Promising Pipeline
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100